Related Experiment Videos
Duodenal ulcer therapy with low-dose antacids: a multicenter trial
1Clinical Research Department, Rhône-Poulenc Rorer, Köln, F.R.G.
Journal of Clinical Gastroenterology
|January 1, 1991
Summary
Low-dose antacid tablets offer effective duodenal ulcer treatment, comparable to misoprostol. This antacid regimen is safe and provides significant relief from night pain during initial therapy.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Duodenal ulcers are common gastrointestinal conditions requiring effective treatment.
- Assessing the efficacy and safety of different therapeutic agents is crucial for patient care.
Purpose of the Study:
- To compare the efficacy and safety of low-dose antacid (AA) versus misoprostol (MS) in treating duodenal ulcers.
- To evaluate the impact of both treatments on clinical symptoms and ulcer healing rates.
Main Methods:
- A double-blind, randomized, multicenter trial involving 100 outpatients with endoscopically verified duodenal ulcers.
- Patients received either low-dose antacid (Supralox) or misoprostol (Cytotec) for up to 4 weeks.
- Endoscopic and clinical evaluations were performed at 2 and 4 weeks.
Main Results:
- After 4 weeks, ulcer healing rates were 79.6% for antacid and 74.4% for misoprostol, with no statistically significant difference.
- Both treatments showed similar overall improvement in clinical symptoms.
- Antacid therapy provided significantly greater relief from night pain during the first 2 weeks.
Conclusions:
- Low-dose antacid tablets are a safe and effective treatment option for duodenal ulcers.
- Antacid therapy demonstrates comparable healing rates to misoprostol with a favorable side effect profile.
- Antacids may offer an advantage in early symptom relief, particularly for night pain.